English
首页  >  我要参观  >  VIP买家

 

荷兰皇家帝斯曼集团

Royal DSM

113年荷兰皇家帝斯曼集团以科技为立足之本,在全球范围内活跃于健康、营养和材料领域。帝斯曼拥有生命科学和材料科学领域的专长,并运用两者的独特结合不断推动经济繁荣、环境改善和社会进步,为所有利益相关方创造可持续的价值。帝斯曼服务于食品和保健品、个人护理、饲料、医疗设备、汽车、涂料与油漆、电子电气、生命防护,替代能源以及生物基材料等终端市场,在全球范围内创造可持续的解决方案,促进营养、增强和保证产品功效、提高产品性能。帝斯曼及其关联公司约25,000名员工创造了约100亿欧元的年销售额。公司已在泛欧阿姆斯特丹交易所上市。帝斯曼早在1963年开始对华贸易,并于上世纪90年代初在中国建立了首个销售代表处和首个生产场地。帝斯曼中国地区总部和研发中心位于上海。目前,公司在中国拥有包括21个生产场地在内的39个分支机构,员工约4200名。帝斯曼在华业务健康稳步增长,2014年中国销售额为20亿美元

 

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam.

 

 

印度太阳药业有限公司

Sun Pharma Industries

印度太阳药业有限公司(Sun Pharma Industries)印度著名的制药公司,于1983年创建,总部设在古吉拉特邦瓦尔道拉,致力于为心血管、精神神经、消化道、呼吸道等疾病以及诸如糖尿病等慢性疾病的治疗提供专科药品及其原料药;1994年上市,是印度市值最大的医药公司;其主要销售市场在美国。

 

 

洛比化学国际公司

ROCHEM

费若宾女士在1984年大学英国语言文学专业毕业后加入到当时国营企业中最大的专业化工公司从事化工,医药原料的进出口贸易工作。怀着年轻人特有的热情她拜访了全国无数家的化工医药生产厂,从而获得了第一手产品知识。通过每年举行的两届广交会,她用这些知识向她结识的无数来自不同国家、地区的用户销售这些产品。这种难得的机会丰富了她的国际贸易意识和经验。在她年仅24岁的时候,她成为中化烟台、也是当时整个外贸系统最年轻的经理。

1990年10月,若宾女士迈出了她实现美国梦的第一步。虽然她双手空空,但是她怀着满腔的自信到达了纽约。她相信“天高任鸟飞,海阔任鱼跃”之说法。她就是那只鸟,美国成为她自由翱翔的天空。

凭借着她多年积累的化工、医药产品经验和与无数工厂建立起来的业务关系和信任,以及她与北美,欧洲用户们的关系,她认为完全可以架起这座连接欧美用户与中国化工,医药原料厂家的桥梁,让双方均都长期受益。于是,在1994年,洛比化学在费若宾女士的家中一间小的办公室中成立了。1996年,在费若宾女士的不断的努力与奋斗下,洛比化学得以发展并且将公司搬进了纽约长岛大颈。梦想经过不懈的耕耘终于实现,2002年费若宾女士买下了现在带有仓库的总部办公楼。经过数年的发展,纽约长岛大颈的办公楼已经无法满足日益发展的洛比的需求,于是,2014年,费若宾女士买下了位于纽约哈帕的崭新的办公楼和仓库,庆祝洛比全新的开始。

美国洛比化学国际公司在全球现有12个办事处。洛比化学的整个精英团队都经过严格筛选,并在医药界拥有非常丰富的知识和经验。若宾女士描述自己是一个梦想家,一个坚信只能依靠严格的原则性,责任心,和努力工作才能实现梦想的梦想家。凭借着与中国顶尖供应商的密切合作,洛比化学赢得了越来越多来自全球客户的赞誉。

 

After graduating college in 1984 with a degree in English Literature, Robyn joined one of the largest Import & Export Trading companies in China handling chemical and pharmaceutical raw materials. With her youthful enthusiasm Robyn traveled throughout China visiting many different chemical and pharmaceutical manufacturers. She created a working knowledge and understanding of the entire sourcing, manufacturing, and supply process. Robyn was exposed to the international business world and excelled at the semi-annual Guangzhou Export Commodity Fair. By the age of 24, she became the youngest manager in the entire Foreign Trade Industry of Sinochem Yantai.

In October of 1990, Robyn took a step towards her American dream. She arrived in New York with two empty hands and a heart filled with determination. An ancient Chinese proverb states “A bird yearns to fly and reach new heights; a fish yearns for the vast ocean to truly swim freely.” Robyn believed that America was to become her sky and she was the bird, ready to fly.

Robyn’s knowledge and experience in the pharmaceutical industry along with growing customers in North America and Europe, served as a strong foundation for taking the entrepreneurial leap. In 1994, ROCHEM International Inc. was founded by Robyn in a small office of her home. In 1996, as a result of Robyn’s ambition and consistent hard work, ROCHEM expanded and re-located to an office building in Great Neck, NY. ROCHEM’s growing hard-working team coupled with Robyn’s constant dedication resulted in yet another expansion and the purchase of an office and warehousing building in Ronkonkoma, NY in 2002. After years of success, ROCHEM’s Ronkonkoma location no longer fit the growing company’s needs and Robyn purchased and fully renovated their current headquarters and warehousing facility located in Hauppauge, NY, which celebrated it’s grand opening in 2014.

ROCHEM now operates out of 13 offices worldwide. ROCHEM’s elite team of employees have all been carefully chosen and have extensive knowledge and experience in the pharmaceutical industry. Robyn describes herself as a dreamer who understands hard work and is guided by strict principles. She vows to continue fulfilling her dream. Working exclusively with top manufacturers in China, ROCHEM has earned a reputation recognized by a growing global clientele.

 

 

诺华集团

Novartis

诺华是全球领先的医药健康企业,总部位于瑞士巴塞尔。诺华业务遍及全球140 多个国家和地区拥有128,000位全职员工,2012 年,全球超过12 亿患者受益于诺华集团的产品。 诺华集团是世界领先的医药健康公司 诺华在医药健康行业拥有领先的市场地位 市值最高的35 家公司之一 2013年,诺华连续第三年蝉联《财富》杂志全球最受尊敬公司制药行业首位 多元化的业务组合 满足不断变化的医疗需求 诺华集团致力于为患者及社会提供创新医药保健解决方案,以满足其日益变化的健康需求 诺华专注于医药保健领域事业发展,拥有创新药品、眼科保健(爱尔康)、成本节约型非专利 药品(山德士)、预防性疫苗及诊断器材、非处方药等多元化的业务组合 诺华是唯一在上述各领域均处于领先位置的公司创新是我们的核心使命 专注于未获满足的医疗需求,激励诺华将科学和对客户的深入了解联系起来,开发新产品, 推动行业标准 创新是诺华集团各业务及职能部门的主要任务 2012年,诺华投入超过90 亿美元用于研发,是行业中最大的研发投资者之一 胸怀责任且恪守道德准则是成功的关键 责任是诺华业务的核心组成部分,是对诺华“关爱生命,呵护健康”使命的强调 诺华积极应用科学及创新,应对全球最大的医疗挑战,改善全球健康状况 2012年,全球超过1亿患者受益于诺华的药品可及性项目 诺华在中国 早在18世纪,嘉基公司就开始在中国推广染料,汽巴与山德士也先后进入中国。1987 年,北京汽巴- 嘉基制药有限公司成立,这就是北京诺华制药有限公司的前身。26年来,诺华从成立初期的数十 人团队,发展到如今遍布神州大地的7000 多名员工。 从一家仅拥有制药业务的企业,成长为涵盖创新专利药、眼科保健、非专利药、消费者保健以及疫苗和诊断的多元化医药健康行业领军者。 26年来,诺华一直用多元化的医药保健组合,满足中国人民不断变化的医疗需求,践行对中国人民的健康承诺。

 

 

印度鲁宾有限公司

Lupin

鲁宾有限公司是一家以创新为主导,在世界范围内为发达国家和发展中国家提供广泛的高品质,低价位的仿制及品牌制剂和原料药的跨国公司。

在鲁宾,我们努力通过在世界范围内为患者提供可负担、可获得的药品,为人们营造健康的生活。我们致力于发现、研发和使创新药物商业化来满足未能被满足的医疗需求。

当成为世界上最大的结核药生产商时,鲁宾首次得到了认可。多年来,公司已提升了价值链,不仅在中间体和原料药方面有所建树,也充分利用其优势在全球范围内建立起制剂业务,足迹遍布美国、印度、日本、澳大利亚、英国、德国、独联体等。

 

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top five pharmaceutical companies in India. Through our sales and marketing headquarters in Baltimore, MD, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies.

Lupin Limited, headquartered in Mumbai, India, is strongly research focused. It has a program for developing New Chemical Entities. The company has a state-of-the-art R&D center in Pune and is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (ACE-inhibitors and cholesterol reducing agents) and has a notable presence in the areas of diabetes, anti-inflammatory and respiratory therapy.

We are building on our parent company's strengths of vertical integration in discovery research, process chemistry, active pharmaceutical ingredient production, formulation development and regulatory filings. Lupin Pharmaceuticals, Inc. is committed to achieving its vision and mission of becoming an innovation led transnational pharmaceutical company.

Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc. says "founded on the strengths of our parent company Lupin Limited, Lupin Pharmaceuticals, Inc. intends to bring a portfolio of generics as well as branded products to the US market."

 

 

阿斯利康

AstraZeneca

阿斯利康是一家以创新为驱动的全球性生物制药企业,专注于研发、生产和销售处方类药品,为医疗行业带去意义深远的变化。

科研与患者是我们工作的重中之重,我们的专长和资源都集中于我们认为最能带来改变的疾病领域。我们主要专注于肿瘤、心血管/代谢、呼吸/炎症/自体免疫等治疗领域。除此之外,我们也积极探索抗感染及神经科学领域的合作机会。

通过创新的科研与卓越的全球商业化发展向患者提供药物是我们取得战略成功的途径。

除了自主研发项目外,我们不断寻求机会与领先的科研机构进行合作以加快新药物的研发。近几年我们积极拓展早期生物技术及学术领域合作,并通过授权和收购等形式加强我们的产品线,为医生和患者提供更广阔的治疗选择。

合作是我们日常工作的一部分。了解患者和医护专业人员的需求,理解监管者和医疗卫生服务支付方的视角,对我们的成功至关重要。我们与这些群体密切合作,汲取他们的深刻见解,研发独特的靶向药物,为医疗行业带来变化。

我们推动业务成功的同时始终坚持承担社会责任,将诚信与高道德标准融入到日常工作,以维护利益相关方们对我们的信任。

改善健康是当今世界面临的最具挑战的问题之一,推动这一领域的发展需要长期付出巨大的努力。阿斯利康致力为这一目标做出重要贡献。

 

We are a global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare.

Science and patients are at the heart of everything we do, and our skills and resources are concentrated on those therapy areas where we believe we can make the most difference. We focus primarily on cancer, cardiovascular/metabolic disease and respiratory/inflammation/autoimmunity. Alongside this, we remain active in infection and neuroscience with targeted investments in opportunities and collaborations.

Our business strategy sets out our path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.

Alongside our own research and development, we continue to partner with others to access the best science and accelerate the delivery of new medicines. We have been active in building early stage biotech and academic alliances in recent years and we want to do more of these, alongside in-licensing and acquisitions to strengthen our pipeline and broaden the range of treatment options for physicians and patients.

More broadly, collaboration is part of everyday business for us. Understanding the needs of patients and healthcare professionals, and the perspectives of regulators and those who pay for healthcare, is critical to our continued success. We work closely with these groups to get the insights we need to deliver distinctive, targeted medicines that make a difference in healthcare.

Across all our activity, we are committed to driving business success responsibly, acting with integrity and working to high ethical standards to maintain the trust of our stakeholders.

Improving health is one of the toughest challenges facing the world today and it will take a sustained and significant effort to drive continued progress. AstraZeneca has a key contribution to make to that effort.

 

 

先声药业

Simcere

先声药业成立于1995年3月28日,至今,已发展成为集生产、研发、销售为一体,拥有6家通过GMP认证的现代化药品生产企业,2家全国性的药品营销企业、1家药物研究院,拥有员工4000余人的新型药业集团。2005年,联想控股公司下属的弘毅投资出资2.1亿元,持有先声药业31%的股份。2007年4月20日,先声药业成功登陆纽约证券交易所,募集资金2.61亿美元,股票代码SCR,成为中国内地第1家在纽交所上市的化学生物药公司。 2008年,先声药业实现销售收入17.41亿元,上缴国家税收3.31亿元,实现净利润3.51亿元。从2002年到2008年,先声药业的年销售额、年净利润复合增长率分别是33.8%和87.7%,远远高于行业平均水平,也强于众多A股上市的医药公司。先声药业正成为在快速增长的中国市场上领先的品牌非专利药生产商和供应商。

 

Founded on 28th March 1995, Simcere has swiftly evolved from a pure pharmaceutical distributor into a leading pharmaceutical manufacturer and supplier in China's rapidly growing pharmaceutical market. Simcere currently operates one research and development center, two nationwide sale and marketing subsidiaries and four GMP manufacturing facilities. It has approximately 4,300 employees in China.

 

 

美国凯华股份有限公司ChemWerth

优质的原料药。目前,凯华公司代表着中国、美国、欧洲和印度众多获FDA批准的CGMP厂商。凯华公司提供全方位的服务,包括一整套的药政事务和技术服务。我们的专业队伍会帮助你推进产品开发进程,并提供创新的化学工艺和进步的技术。凯华公司向全世界的药政部门注册产品,并提供多方面的药政和技术支持来推进其批准的进程。凯华公司确保我们的产品在现有专利法的范围内制造。

凯华公司提供无间隙的清关和物流支持, 减少原料药运输中的不必要延迟。我们承诺通过我们公司供应的产品,符合甚至超越我们客户和药政官方的标准。

 

21st Century economic, social, technical and regulatory dynamics are dramatically changing the pharmaceutical world making it more challenging than ever to find profitable opportunities. That's why it's important to work with a supply-partner who knows how to navigate through the tough issues, help you overcome obstacles and get you to the market fast to gain competitive advantage. ChemWerth is that supply-partner!

Established in 1982, ChemWerth is a full service generic drug development and supply company providing high quality Active Pharmaceutical Ingredients to regulated markets worldwide.

 

 

德国拜耳集团

Bayer

拜耳是一家在医药保健、作物营养领域拥有核心竞争力的全球性企业。我们坚持以人为本,以自身产品与服务提升人类生活品质;同时致力于以创新、成长与高盈利能力创造更多价值。

拜耳公司秉承"拜耳——科技创造美好生活"的使命,持续优化产品组合,将活动集中于三大富有潜力、效率和独立性的子集团 —— 拜耳医药保健、拜耳作物科学、拜耳材料科技,并由三家服务公司为其提供各项支持。各运营公司均以其卓越贡献,有力地推动了全球主要市场的发展。作为一家发明型企业,拜耳将继续在研发密集型领域引领潮流。创新是竞争力之基,是发展之源,也是企业未来成功之关键所在。

拜耳公司以其专业技术和产品,协助诊断、减轻和治愈疾病,提升全球食品供应的数量和质量,并为积极向上的现代化生活方式做出了巨大贡献。凭借专业技术与创新品质,我们能够为环境保护提供解决方案,并发布气候变化的影响结果。

 

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earning power.

We are firmly aligned to our mission statement "Bayer: Science For A Better Life" and continue to optimize our portfolio, concentrating our activities in three high-potential, efficient subgroups with largely independent operations: HealthCare, CropScience and MaterialScience. These provide us with access to major global groth markets and are supported by our service companies.

As an inventor company, we plan to continue setting trends in research-intensive areas. Innovation is the foundation for competitiveness and growth, and thus for our company's success in the future.

Our knowledge and our products are helping to diagnose, alleviate or cure diseases, improving the quality and adequacy of the global food supply, and contributing significantly to an active, modern lifestyle. Our expertise and innovative capability also enable us to offer solutions for protecting the climate and addressing the consequences of climate change.

 

 

Antibioticos S.P.A.

The continuous development of our management structure has led to the creation of product management and technical service functions within marketing and sales management. We enhance the promotion of better customer relationships and market information. Training activities for our facilities personnel continue, with special emphasis on the development of managerial capabilities. We are expanding our activities in the development of new processes and products in the booming biotechnological area. Also, we are open to cooperation through a responsible partnership approach, based on the quality and reliability of our products and services. Our aim is to further strengthen our relations with customers to ensure a long term sustained profitability. We retain an important share in the global market thanks to strict quality control, investment in R&D know-how expertise, human resources as well as vertical and international integration. We are a strong key partner of the multinational pharmaceutical companies for the production of Active Pharmaceutical Ingredients. We sell our products in more than 50 countries worldwide. Our plant operate in compliance with GMP. We offer Contract manufacturing services to multinational corporations, large pharmaceutical organizations and other companies who would like to outsource products for toll manufacturing.

 

 

鲁南制药集团

Lunan Pharmaceutica

鲁南制药集团是集中药、西药、生物制药的生产、科研、销售于一体的国家大型综合制药集团、国家重点高新技术企业,成员企业包括鲁南厚普制药有限公司、鲁南贝特制药有限公司、山东新时代药业有限公司、鲁南新时代医药有限公司等八家子公司,位列中国大企业集团竞争力500强,连续七年荣登山东省纳税100强榜。 鲁南制药集团重视科技创新,设有国家手性制药工程技术研究中心、哺乳动物细胞高效表达国家工程实验室、中药制药共性技术国家重点实验室、国家级企业技术中心、博士后科研工作站、“泰山学者”岗位等科研平台。在加强自主创新体系建设的同时,企业与100余所国内外知名院所建立了长期合作关系,成功地完成了400多项研究课题,多次承担国家科技支撑计划、国家863计划、国家重大新药创制专项、国家火炬计划、国家重点新产品计划,100多个项目获得科技奖项,其中国家科技进步二等奖6项。近年来已申报国际、国内发明专利900多项,已获授权专利500多项,荣获“国家技术创新示范企业”、“国家创新型企业”等称号,集团科技创新能力居全国同行业前列。

 

Lunan Pharmaceutical Group Corporation is a major national hi-tech enterprise and National Key High New Technology Enterprise that produces, researches and sells both traditional Chinese medicine, chemical medicine and bio-pharmaceutical medicinal products.

The group is comprised of eight subsidiary companies including Lunan Hope Pharmaceutical Co., LTD., Lunan Better Pharmaceutical Co., LTD., Shandong New Time Pharmaceutical Co., LTD., Lunan New Time Bio-Tech Co., LTD. etc.. It is an energetic and potential enterprise that has more than 9000employees with an average age of 30 and 80% graduated form colleges. In 2015, the total sale revenues reached 1.1 billion dollars.

 

 

山东新华制药厂股份有限公司

Shandong Xinhuan Pharmaceutical Co,LTD.

新华制药的前身是1943年成立于胶东抗日根据地的山东新华制药厂。公司占地近300多万平方米,现有职工4000多人。是我国重点骨干大型制药企业、亚洲最大的解热镇痛类药物生产与出口基地,以及国内重要的心脑血管类、抗感染类及中枢神经类等药物生产企业。在我国化工及医药行业具有较高的企业地位和影响力。公司是H股、A股上市公司,是中国医药工业十佳技术创新企业,中国制药工业50强。目前旗下有9家控股子公司。“新华牌”商标是中国驰名商标,是商务部重点培育和发展的出口品牌。

目前,公司年产化学原料药总量2.5万吨以上,是全球最大的安乃近、布洛芬、阿司匹林、咖啡因、左旋多巴等药物生产企业,拥有乙氧苯柳胺等10个原料药独家品种,8个原料药主导品种市场占有率居国内第一位,制剂年生产能力为片剂达80亿片、针剂3亿支、胶囊2亿粒。公司从创业之初,始终坚持技术第一、质量第一,奉行“产品质量关系企业生命,药品质量关系人的生命”的质量理念,生产上严把质量关,精益求精。公司是国内首家通过ISO9001、ISO14001、ISO10012三项认证的医药化工企业,所有在产原料药产品、制剂剂型均已通过GMP认证,茶碱、布洛芬等8个产品通过了美国FDA认证,茶碱、阿司匹林等10个产品获得了欧洲COS证书,咖啡因产品通过了美国用户的社会责任认证、环境认证,以及中国食品安全体系(HACCP)认证。同时有多个产品在俄罗斯、印度等国家完成了注册。大部分主导品种主要技经指标居国内领先地位,高于国内国际认证标准。

 

 

英国葛兰素史克公司

GSK

葛兰素史克(GSK),以研发为基础的药品和保健品公司,年产药品40亿盒,产品遍及全球市场。

葛兰素史克由葛兰素威康和史克必成合并而成,于2000年12月成立。两家公司的历史均可追溯至19世纪中叶,各自在一个多世纪的不断创新和数次合并中,在医药领域都确立了世界级的领先地位。葛兰素史克公司在抗感染、中枢神经系统、呼吸和胃肠道/代谢四大医疗领域代表当今世界的最高水平,在疫苗领域和抗肿瘤药物方面也雄居行业榜首。此外,公司在消费保健领域也居世界领先地位,主要产品包括非处方药、口腔护理品和营养保健饮料。

 

 

默克密理博公司

Merck Millipore

在2015年年底,默克密理博与Sigma-Aldrich合为一体。合并后的公司在美国和加拿大以MilliporeSigma名称运营,是默克集团的生命科学业务部 – 默克集团是1250亿美元生命科学行业的领头羊。

我们的共同目标是通过与全球科学界合作,解决生命科学中最棘手的问题。如今,我们提供300,000多种产品,包括业内许多最受推崇的品牌。我们的产品和服务涵盖生物技术和生物制药生产链的每个环节,通过高水准的客户服务、简化的界面以及先进的电子商务和分销平台,创建完美的端对端工作流程。

默克的生命科学业务部在世界各地有65个生产基地,员工人数超过19,000人,遍布66个国家。广泛的地域分布、创新的产品组合、行业领先的业务能力、以及鼓励求知欲和合作精神的企业文化,都将我们置于一个独特的位置,让我们得以预测和满足客户的需求,并帮助他们解决最棘手的生命科学难题。

 

In late 2015, Merck Millipore joined forces with Sigma-Aldrich. Our combined organization, which operates as MilliporeSigma in the United States and Canada, is the life science business of Merck – and a global leader in the $125 billion life science industry.

Our shared purpose is to solve the toughest problems in life science by collaborating with the global scientific community. Together, we offer a broad portfolio of more than 300,000 products, including many of the most highly respected brands in the industry. Our offerings span every step of the biotech/biopharma production chain, creating a complete end-to-end workflow with enhanced customer service, a simplified interface and a leading e-commerce and distribution platform.

Merck’s life science business operates 65 manufacturing sites worldwide and employs more than 19,000 people in 66 countries. This geographic reach, combined with our innovative portfolio, industry-leading capabilities, and a culture that fosters curiosity and collaboration, uniquely positions us to anticipate and fulfill our customers’ needs – and solve their toughest life science problems.

 

 

丽珠医药集团股份有限公司

Livzon

丽珠医药集团股份有限公司是集医药研发、生产、销售为一体的综合性企业集团,创建于1985年1月,注册资本为3.9亿元。集团现拥有18个专利产品,21个独家产品,其中参芪扶正注射液和艾普拉唑先后荣获广东省科技进步一等奖。2016年1月,集团原研新药艾普拉唑又荣获国家科技进步二等奖殊荣。

近几年来,公司先后获得国内多个行业荣誉:2011年被评为中国最具竞争力医药上市公司20强,2012年被评为最佳上市企业治理10强;2013年被评为上市企业投资价值TOP10强,2014-2015年被评为中国最具品牌价值500强企业。

丽珠系中国医药50强、国家技术创新示范企业。2014年完成了B转H股,系行业第一家。2016年,集团将整体搬迁至金湾区丽珠工业园,丽珠工业园占地42.7万平方米,总投资约20亿元人民币,是按美国FDA和欧盟标准建造的国际一流的现代化制药生产基地。

公司永远致力于人类健康事业,提供国内领先、国际一流的特色专科药,公司正致力于向生物制药的战略转型,开拓布局“精准医疗”领域!根据公司发展战略,到2017年将实现销售目标100亿的目标。

 

Livzon Pharmaceutical Group Inc., founded in 1985, is a comprehensive pharmaceutical enterprise integrating development & research, production and sales of pharmaceutical products. Livzon has 9 GMP production plants located in Guangdong, Shanghai, Sichuan, Fujian, 3 plantation bases for Chinese drug preparation production located in Shanxi, Gansu, Yunan of China, with more than 5,700 employees.

Livzon has modern industrial chain and product group, operates to manufacture drug preparation, bulk medicines and intermediates, as well as diagnostic reagents and equipment, with approximate 280 products therapeutically grouped as gastrointestinal, cardio-cerebral-vascular, anti-biotic, gonadotropic hormone etc. Meanwhile, Livzon possesses production bases as leading manufacturer of Chinese drug preparation injection, and specialist bulk medicines and intermediates such as fermented antibiotics, sterile cephalosporins, and hypolipidemic “statins”.

All production lines are compliant with GMP requirements, including some DMFs, USA FDA inspection and COS approvals etc. Benefited from the regulatory compliance, an extensive overseas market is under robust development, including India, Japan, Eastern Europe for bulk medicines and intermediates, and the Philippines, Kyrgyzstan, Uzbekistan, Tajikistan, Hong Kong and Pakistan for drug preparation.

In recent years, Livzon implement the strategic transformation of R&D, focusing to antibody medicines and vaccines, and it has already established laboratories of antibody medicines and vaccine development. At the meanwhile, Livzon adjusts R&D direction of chemical pharmaceutical for carrying out transformation and upgrade. Livzon forms a complete research system. In addition, Livzon has established long-term cooperative relationship with more than 30 domestic and overseas scientific research institutes.